Ventripoint to Showcase AI-Powered Cardiac Imaging at European Paediatric Cardiology Conference
Ventripoint will exhibit its VMS+ 4.0 technology at the AEPC annual meeting, highlighting its potential to improve lifelong care for congenital heart disease patients through accurate, MRI-equivalent assessments from echocardiograms.
Ventripoint Diagnostics Ltd., a leader in applying artificial intelligence to echocardiography, will participate in the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) from May 12-16, 2026, in Padua, Italy. The event brings together over 1,000 specialists from 32 European countries and beyond, representing the world’s largest association in congenital cardiology.
The timing of Ventripoint’s presence at the conference is significant. The scientific program this year focuses on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint’s VMS+ product family is driving clinical progress. The company will exhibit alongside its European distributor, AngioPro, and plans to engage with clinicians about the benefits of using VMS+ to monitor cardiac function over time in patients with congenital heart disease (CHD).
The importance of longitudinal monitoring is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC. These guidelines recognize CHD as a lifelong chronic condition requiring structured, individualized follow-up, and affirm echocardiography as the key modality for assessing ventricular function over time (Baumgartner et al., European Heart Journal, 2021). Ventripoint’s VMS+ technology addresses this need by providing accurate volumetric cardiac measurements equivalent to MRI, but from a standard echocardiogram, enabling earlier and more accessible insights.
Ventripoint’s priority for 2026 is accelerating the integration of VMS+ into routine clinical practice. The latest release, VMS+ 4.0, was designed to streamline workflows and reduce the time required to generate assessments, making advanced cardiac analysis accessible at the point of care. According to the company, at the time of a patient’s first echocardiogram, VMS+ delivers detailed insights that support clinical decision-making and more effective patient management across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint’s VMS+ product family is powered by proprietary KBR technology, the result of more than a decade of development. It holds regulatory approvals in the U.S., Europe, and Canada, and is compatible with ultrasound systems from all major vendors. The company’s participation in the AEPC meeting signals its commitment to expanding its footprint in the European congenital cardiology market and to supporting the shift toward more proactive, data-driven management of CHD patients.